A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00262288 Phase 2/Phase 3 COMPLETED

The purpose of this multi-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.

Details

Lead sponsor	Pharming Technologies B.V.
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	14
Start date	2004-04
Completion	2007-01

Conditions

• Genetic Disorders

Interventions

• i.v. recombinant human C1 inhibitor

Primary outcomes

• Primary outcomes: Relief of angioedema symptoms — 24 hours

Countries

Netherlands